0.8813
price up icon1.29%   0.0213
 
loading
Schlusskurs vom Vortag:
$0.86
Offen:
$0.86
24-Stunden-Volumen:
36,641
Relative Volume:
0.30
Marktkapitalisierung:
$12.99M
Einnahmen:
$500.00K
Nettoeinkommen (Verlust:
$-19.45M
KGV:
-0.4663
EPS:
-1.89
Netto-Cashflow:
$-18.22M
1W Leistung:
-0.10%
1M Leistung:
-20.08%
6M Leistung:
-9.17%
1J Leistung:
-35.70%
1-Tages-Spanne:
Value
$0.8316
$0.8996
1-Wochen-Bereich:
Value
$0.8316
$0.9079
52-Wochen-Spanne:
Value
$0.64
$3.65

Imunon Inc Stock (IMNN) Company Profile

Name
Firmenname
Imunon Inc
Name
Telefon
(609) 896-9100
Name
Adresse
997 LENOX DRIVE, LAWRENCEVILLE
Name
Mitarbeiter
25
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
IMNN's Discussions on Twitter

Vergleichen Sie IMNN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMNN
Imunon Inc
0.87 12.99M 500.00K -19.45M -18.22M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
506.79 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
570.72 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
632.41 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.19 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
250.03 24.70B 3.81B -644.79M -669.77M -6.24

Imunon Inc Aktie (IMNN) Neueste Nachrichten

pulisher
Apr 27, 2025

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - ADVFN

Apr 27, 2025
pulisher
Apr 23, 2025

Imunon, Inc. (NASDAQ:IMNN) Sees Significant Growth in Short Interest - Defense World

Apr 23, 2025
pulisher
Apr 21, 2025

Imunon announces IMNN-001 abstract accepted for oral presentation at 2025 ASCO - TipRanks

Apr 21, 2025
pulisher
Apr 21, 2025

IMUNON (IMNN) Reveals Promising Survival Data for Advanced Ovari - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting | IMNN Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

IMUNON, Inc. Announces Presentation of Promising Overall Survival Data from Phase 2 OVATION 2 Study for Advanced Ovarian Cancer and Initiation of Phase 3 Trial Sites for IMNN-001 - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewswire

Apr 21, 2025
pulisher
Apr 21, 2025

First Effective IL-12 Immunotherapy Shows Survival Benefits in Advanced Ovarian CancerASCO 2025 Preview - Stock Titan

Apr 21, 2025
pulisher
Apr 17, 2025

Imunon (NASDAQ:IMNN) Trading Down 1.9% – Time to Sell? - Defense World

Apr 17, 2025
pulisher
Apr 09, 2025

Celsion Corporation Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board - marketscreener.com

Apr 09, 2025
pulisher
Apr 04, 2025

Imunon (IMNN) Files to Sell 10 Million Shares, Warrants - GuruFocus

Apr 04, 2025
pulisher
Apr 01, 2025

DNA Vaccines Offer a New Path Beyond mRNA Technology - Technology Networks

Apr 01, 2025
pulisher
Apr 01, 2025

Stacy Lindborg, PhD's Profile Page - Technology Networks

Apr 01, 2025
pulisher
Mar 31, 2025

Companies To Watch: Imunon - Life Science Leader

Mar 31, 2025
pulisher
Mar 28, 2025

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer - Smartkarma

Mar 28, 2025
pulisher
Mar 28, 2025

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Zacks Small Cap Research

Mar 28, 2025
pulisher
Mar 28, 2025

Imunon (NASDAQ:IMNN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment - Yahoo

Mar 25, 2025
pulisher
Mar 25, 2025

Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Imunon finalizes Phase 3 study design with FDA for IMNN-001 - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan

Mar 24, 2025
pulisher
Mar 07, 2025

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagionlive.com

Mar 07, 2025
pulisher
Mar 03, 2025

Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges - TipRanks

Mar 03, 2025
pulisher
Mar 02, 2025

Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Imunon’s Strategic Clinical Advancements and Promising Research Drive Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025 - Smartkarma

Feb 28, 2025
pulisher
Feb 28, 2025

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

IMUNON, Inc. Reports 2024 Financial Results and Advances Clinical Programs - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Earnings call transcript: Imunon Q4 2024 reports improved EPS, stock declines - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Imunon Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business Update - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON's Cancer Immunotherapy Shows 13-Month Survival Benefit in Ovarian Cancer | IMNN Stock News - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial - Yahoo Finance

Feb 27, 2025
pulisher
Feb 26, 2025

Imunon announces new analyses of results from Phase 1 trial of IMNN-101 - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages - StockTitan

Feb 26, 2025
pulisher
Feb 22, 2025

Imunon (IMNN) Expected to Announce Quarterly Earnings on Thursday - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

Imunon Inc [IMNN] Shares Jump Approximately 66.98% Over the Year - Knox Daily

Feb 20, 2025
pulisher
Feb 20, 2025

The time has not yet come to remove your chips from the table: Imunon Inc (IMNN) - SETE News

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON, Inc. to Announce Full Year 2024 Financial Results on February 27, 2025 - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter

Feb 20, 2025
pulisher
Feb 20, 2025

IMNNImunon Inc Latest Stock News & Market Updates - Stock Titan

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire

Feb 20, 2025

Finanzdaten der Imunon Inc-Aktie (IMNN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Imunon Inc-Aktie (IMNN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lindborg Stacy
President and CEO
Aug 15 '24
Buy
0.98
25,000
24,500
264,166
Tardugno Michael H
Executive Chairman of Board
Aug 15 '24
Buy
1.03
25,000
25,750
353,346
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
Kapitalisierung:     |  Volumen (24h):